Similarly, in the other two human NSCLC cell lines (H1299 and H1703), GH and pegvisomant treatments did not alter the phosphorylation status of SRC (Figure 2B,C), which is consistent with tumor samples of NSCLC patients (Figure 2A). This evidence concerns the gene GH1 and neoplasm.